FN Clarivate Analytics Web of Science
VR 1.0
PT J
AU Yates, LR
   Gerstung, M
   Knappskog, S
   Desmedt, C
   Gundem, G
   Van Loo, P
   Aas, T
   Alexandrov, LB
   Larsimont, D
   Davies, H
   Li, YL
   Ju, YS
   Ramakrishna, M
   Haugland, HK
   Lilleng, PK
   Nik-Zainal, S
   McLaren, S
   Butler, A
   Martin, S
   Glodzik, D
   Menzies, A
   Raine, K
   Hinton, J
   Jones, D
   Mudie, LJ
   Jiang, B
   Vincent, D
   Greene-Colozzi, A
   Adnet, PY
   Fatima, A
   Maetens, M
   Ignatiadis, M
   Stratton, MR
   Sotiriou, C
   Richardson, AL
   Lonning, PE
   Wedge, DC
   Campbell, PJ
AF Yates, Lucy R.
   Gerstung, Moritz
   Knappskog, Stian
   Desmedt, Christine
   Gundem, Gunes
   Van Loo, Peter
   Aas, Turid
   Alexandrov, Ludmil B.
   Larsimont, Denis
   Davies, Helen
   Li, Yilong
   Ju, Young Seok
   Ramakrishna, Manasa
   Haugland, Hans Kristian
   Lilleng, Peer Kaare
   Nik-Zainal, Serena
   McLaren, Stuart
   Butler, Adam
   Martin, Sancha
   Glodzik, Dominic
   Menzies, Andrew
   Raine, Keiran
   Hinton, Jonathan
   Jones, David
   Mudie, Laura J.
   Jiang, Bing
   Vincent, Delphine
   Greene-Colozzi, April
   Adnet, Pierre-Yves
   Fatima, Aquila
   Maetens, Marion
   Ignatiadis, Michail
   Stratton, Michael R.
   Sotiriou, Christos
   Richardson, Andrea L.
   Lonning, Per Eystein
   Wedge, David C.
   Campbell, Peter J.
TI Subclonal diversification of primary breast cancer revealed by
   multiregion sequencing
SO NATURE MEDICINE
AB The sequencing of cancer genomes may enable tailoring of therapeutics to the underlying biological abnormalities driving a particular patient's tumor. However, sequencing-based strategies rely heavily on representative sampling of tumors. To understand the subclonal structure of primary breast cancer, we applied whole-genome and targeted sequencing to multiple samples from each of 50 patients' tumors (303 samples in total). The extent of subclonal diversification varied among cases and followed spatial patterns. No strict temporal order was evident, with point mutations and rearrangements affecting the most common breast cancer genes, including PIK3CA, TP53, PTEN, BRCA2 and MYC, occurring early in some tumors and late in others. In 13 out of 50 cancers, potentially targetable mutations were subclonal. Landmarks of disease progression, such as resistance to chemotherapy and the acquisition of invasive or metastatic potential, arose within detectable subclones of antecedent lesions. These findings highlight the importance of including analyses of subclonal structure and tumor evolution in clinical trials of primary breast cancer.
RI Desmedt, Christine/P-7438-2017; Ju, Young Seok/E-1324-2012
OI Desmedt, Christine/0000-0002-5223-5579; Ju, Young
   Seok/0000-0002-5514-4189; Alexandrov, Ludmil/0000-0003-3596-4515; Van
   Loo, Peter/0000-0003-0292-1949; Martin, Sancha/0000-0001-6213-5259;
   Knappskog, Stian/0000-0002-4153-1655; Wedge, David/0000-0002-7572-3196;
   Gerstung, Moritz/0000-0001-6709-963X; Lonning, Per
   Eystein/0000-0002-8890-6303; Glodzik, Dominik/0000-0001-8112-9073
SN 1078-8956
EI 1546-170X
PD JUL
PY 2015
VL 21
IS 7
BP 751
EP +
DI 10.1038/nm.3886
UT WOS:000357604600016
PM 26099045
ER

EF